Yuki Noguchi
👤 SpeakerAppearances Over Time
Podcast Appearances
The Lung Association says that's imperiled programs like state's quit lines, which offer phone or tech support to smokers trying to quit.
Normally GLP-1 medicines like Wegovy and Zepbound are prescribed for people whose body mass index indicates they are overweight or obese.
But there are also people like Christy Woodard, who at 125 pounds is no longer overweight, but takes a GLP-1 drug.
She's on them because the bariatric surgery she got four years ago did not eliminate some of the hormonal factors that drove her weight gain.
Doctors' views about the benefits of GLP-1s vary.
Many say body size is not the only indicator.
The Centers for Disease Control and Prevention's National Institute of Occupational Safety and Health helps set standards and limits for things like workplace exposure to chemicals or respiratory hazards.
Last April, Health and Human Services Secretary Robert F. Kennedy Jr.
slashed 90 percent of its staff and budget, then brought back about a third of the agency, including at the coal miners' surveillance program under congressional pressure.
As of this week, HHS reversed course on an additional 400 workers who'd received layoff notices.
The unit representing the workers say it will take time to restart the work that was idled.
The analysis reviewed 37 studies with over 9,000 participants and found that people regained weight steadily after quitting weight loss treatments.
Those using the new GLP-1 drugs gained back weight faster, on average within one and a half years, compared to people relying on behavioral changes.
metabolic health gains also reversed.
Those who used behavioral change also regained weight, but over a slightly longer period, 1.7 years.
The finding, published in the medical journal The BMJ, points to one of the major concerns of the new drugs.
Their effects fade quickly after people stop taking them.